Generative artificial intelligence (AI) has absolutely exploded onto the scene. It's become a top strategic priority in the ...

Mayo Clinic researchers have developed a new way to predict whether existing drugs could be repurposed to treat heart failure ...

In this video interview, Umesh Chaudhari, executive medical director and global program head of the C5 programs at Regeneron, ...

Incyte (INCY) announced new 24-week interim data evaluating the safety and efficacy of povorcitinib, an oral small-molecule highly-selective JAK1 ...

Pharmaceuticals announced the presentation of clinical data from the company’s Phase 2b PROGRESS study for its investigational, ...

Some of Sanofi’s most high-profile readouts this year can’t have made for easy reading at the French pharma’s Paris ...

Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to ...

ProteinQure, a Toronto-based biotech company pioneering computational peptide drug discovery, today announced the successful dosing of the first patient in its Phase I clinical trial evaluating PQ203 ...

Exero Medical has completed the enrolment phase for a clinical trial to evaluate the xBar system in monitoring the ...

Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and ...

A drug called riluzole, commonly used to treat amyotrophic lateral sclerosis (ALS) and other motor neuron diseases, could ...

HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of ...